This rationale is also predicated on the fact that DNA-PK activation and gene expression have been shown to be elevated in a number of tumor types, including chronic lymphocytic leukemia, ovarian cancer, and hepatocellular cancer (HCC), and correlate with a poor outcome to standard therapies (12–14). Here, PRKDC is linked to neoplasm.